Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
Xingsheng Hu(Capital Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Pengxiang Wu(Betta Pharmaceuticals (China)), Mengxing Yao, Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Bei Hu(Huazhong Agricultural University), Ying Luo(University of Science and Technology of China), Xinge Cui(Chongqing Normal University), Xiaobin Yuan(Betta Pharmaceuticals (China)), Xin Zheng(Wuhan Union Hospital), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Hui Zhao(Dalian Medical University), Ziping Wang(University of Science and Technology of China), Lieming Ding(Betta Pharmaceuticals (China)), Mingxia Wang(Hebei Medical University), Yunpeng Liu(Shenyang Institute of Automation), Da Jiang(Hebei Medical University), Yang Wang(Shandong Normal University), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 8
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551